Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience.

Sujit ChaudhuriAgnibha DuttaSunil Baran Das Chakraborty

Published in: JGH open : an open access journal of gastroenterology and hepatology (2023)

Saroglitazar is effective and safe in improving biochemical parameters and LSM and CAP values irrespective of weight reduction. It may be used in compensated cirrhotics with close monitoring for side effects.

Keyphrases

tertiary care
end stage renal disease
ejection fraction
type diabetes
chronic kidney disease
peritoneal dialysis
body mass index
prognostic factors
physical activity
weight loss
glycemic control